Evofem Biosciences (EVFM)
OTHER OTC:EVFM
Want to see EVFM full AI Analyst Report?
Top Page
Evofem Biosciences
(OTC:EVFM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.01
▲(0.00% Upside)
Action:Reiterated
Date:05/16/26
The score is primarily held down by weak financial fundamentals—especially the highly stressed balance sheet (negative equity and elevated debt) plus continued negative free cash flow and volatile profitability. Corporate events are a relative positive, highlighted by a new distribution deal and a reported operating-profit year, but valuation is difficult to support with negative earnings and missing dividend data, and technicals cannot be fully assessed due to missing indicators.
Positive Factors
High gross margin
A ~75% gross margin from the product mix (Phexxi, Solosec) provides a durable profitability lever: as sales scale, high gross margins can convert incremental revenue into operating income, helping absorb fixed costs and support reinvestment in commercialization and R&D over months.
Negative Factors
Highly leveraged, negative equity
Deeply negative equity and sizable debt create a thin capitalization profile that materially raises insolvency and refinancing risk. This restricts financing options, invites creditor controls or covenants, and increases the likelihood of dilutive or expensive financing, undermining long-term flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin
A ~75% gross margin from the product mix (Phexxi, Solosec) provides a durable profitability lever: as sales scale, high gross margins can convert incremental revenue into operating income, helping absorb fixed costs and support reinvestment in commercialization and R&D over months.
Read all positive factors
Evofem Biosciences (EVFM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$887.95K
Dividend YieldN/A
Average Volume (3M)589.38K
Price to Earnings (P/E)―
Beta (1Y)-0.06
Revenue Growth4.23%
EPS GrowthN/A
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding132,530,080
10 Day Avg. Volume412,838
30 Day Avg. Volume589,380
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.02
Price to Sales (P/S)0.06
P/FCF Ratio-0.59
Enterprise Value/Market Cap73.68
Enterprise Value/Revenue3.38
Enterprise Value/Gross Profit4.49
Enterprise Value/Ebitda-21.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.5
Revenue Forecast (FY)$241.13M
Evofem Biosciences Business Overview & Revenue Model
Company Description
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. ...
How the Company Makes Money
null...
Evofem Biosciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.34M | 20.18M | 19.36M | 18.22M | 16.84M | 8.24M |
| Gross Profit | 14.59M | 15.07M | 15.53M | 11.71M | 12.42M | 4.19M |
| EBITDA | -3.06M | 2.06M | -6.92M | -16.07M | -82.08M | -165.78M |
| Net Income | -6.05M | 391.00K | -8.86M | 52.98M | -76.70M | -205.19M |
Balance Sheet | ||||||
| Total Assets | 7.44M | 20.27M | 23.79M | 10.55M | 25.16M | 42.51M |
| Cash, Cash Equivalents and Short-Term Investments | 2.38M | 578.00K | 741.00K | 580.00K | 2.77M | 7.73M |
| Total Debt | 66.92M | 65.87M | 45.97M | 43.37M | 71.13M | 115.68M |
| Total Liabilities | 80.15M | 89.71M | 95.05M | 77.06M | 96.96M | 142.09M |
| Stockholders Equity | -72.71M | -69.44M | -71.26M | -66.51M | -71.80M | -99.58M |
Cash Flow | ||||||
| Free Cash Flow | -258.00K | -2.00M | -3.90M | -8.97M | -70.75M | -149.61M |
| Operating Cash Flow | -251.00K | -1.99M | -3.88M | -8.97M | -70.41M | -146.67M |
| Investing Cash Flow | 50.00K | -62.00K | -569.00K | -4.00K | -341.00K | -2.69M |
| Financing Cash Flow | 1.53M | 1.89M | 4.62M | 4.78M | 61.94M | 90.69M |
Evofem Biosciences Risk Analysis
Evofem Biosciences disclosed 106 risk factors in its most recent earnings report. Evofem Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our strategy relating to potential mergers and acquisitions involves a number of risks and we have a limited history of such activity. Even if an acquisition or merger is completed, it may not produce results as positive as management may have projected. Q3, 2023
Evofem Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
EVFM
Evofem Biosciences
0.01
0.00
0.00%
QCLS
Q/C Technologies
4.33
-14.56
-77.08%
DARE
Daré Bioscience
2.17
-0.72
-24.91%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.61
-1.83
-41.22%
Evofem Biosciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Evofem Biosciences Secures Solosec Distribution Deal in Africa
Positive
Apr 30, 2026
On April 24, 2026, Evofem Biosciences, Inc. entered into an exclusive five-year agreement with Clovis Davis Pharmaceuticals, LLC to distribute, promote, market, and sell Solosec (secnidazole) 2 g oral granules in sub-Saharan Africa. Local regulato...
Private Placements and Financing
Evofem Biosciences Amends Convertible Note Financing Terms
Neutral
Apr 16, 2026
On April 10, 2026, Evofem Biosciences, Inc. and funds affiliated with Adjuvant Global Health Technology Fund entered into a fourth amendment to their existing Securities Purchase Agreement governing certain convertible promissory notes. This amend...
Business Operations and StrategyFinancial Disclosures
Evofem Biosciences Reports First Year of Operating Profit
Positive
Mar 12, 2026
On March 11, 2026, Evofem Biosciences reported financial results for the fourth quarter and full year 2025, marking its fifth consecutive year of net sales growth and its first year of positive operating income. Full-year net sales rose 4% to a re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.